The weekly litigation news digest is live. Subscribe now
Piperidin-4-Yl Azetidine Derivatives As Jak1 Inhibitors - EP3050882
The patent EP3050882 was granted to Incyte on Jan 31, 2018. The application was filed on Mar 9, 2011 under application number EP15195698A. The patent is currently recorded with a legal status of "Revoked".
EP3050882
- Application Number
- EP15195698A
- Filing Date
- Mar 9, 2011
- Status
- Revoked
- Jul 12, 2019
- Publication Date
- Jan 31, 2018
- External Links
- Slate, Register, Google Patents
Patent Summary
Selective JAK1 inhibitors for treating diseases associated with JAK1 overactivity, such as autoimmune disorders, allograft rejection, and cancers. The compounds are derived from a specific chemical structure and have selectivity for inhibiting JAK1 over other JAKs like JAK2, JAK3, and TYK2. This provides therapeutic advantages by avoiding unnecessary immunosuppression and anemia/bleeding side effects associated with less selective JAK inhibitors. The compounds can be administered alone or in combination therapies for treating diseases involving JAK1 overactivity.
Patent Family
Patent Oppositions
Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
Patent Citations (30) New
Patent citations refer to prior patents cited during different phases such as opposition or international search.
Dossier Documents
The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.
Date
Description
Get instant alerts for new documents